article thumbnail

Subcutaneous Biologics: The Unmet Requirement in the Pharmaceutical Space

Roots Analysis

Subcutaneous drug delivery systems – the helping hand for patients. There has been a significant increase in the number of biologics, specifically the new generation molecules, such as monoclonal antibodies, in the late-stage clinical studies ( phase II / phase III ). Our Social Media Platform. Web: [link].

article thumbnail

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to.

The Pharma Data

Additionally, Janssen will present an update on the Phase 3 SunRISe-2 trial evaluating an investigational intravesical drug delivery system, TAR-200, in combination with the programmed cell death receptor-1 (PD-1) inhibitor cetrelimab in muscle-invasive urothelial carcinoma (Abstract # MP13-17). [1]. About TAR-200.